Original StudyAssociation Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non–small-cell Lung Cancer
Introduction
Lung cancer, including 85% of non–small-cell lung cancer (NSCLC),1 remains the most common cause of cancer-related death.2
New treatment options, such as immune checkpoint inhibitors (ICIs), are approved for the treatment of naive and relapsing advanced NSCLC. ICIs target and inhibit programmed cell death protein 1 on T cells (anti-PD-1) or its ligand (PD-L1) on tumor cells (anti-PD-L1) or on tumor microenvironment cells to enhance anti-tumor immunity.3
Until recently, ICIs have been primarily used for the second-line treatment of advanced NSCLC. To date, 3 drugs have been approved by the United States Food and Drug Administration based on 4 phase III clinical trials demonstrating the superiority of ICIs over standard docetaxel.4, 5, 6 ICIs are now also registered in the first-line setting alone or in combination with chemotherapy as a result of the Keynote024 (phase III trial of pembrolizumab (MK-3475) vs platinum-based chemotherapy as first-line therapy for patients with metastatic non-small cell lung cancer (NSCLC) that expresses programmed cell death ligand 1) and 021G (Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study) trials.5, 7
Releasing the brakes of the host-immune system, ICIs may alter the physiologic homeostasis of immune response, thus leading to the development of immune-related adverse events (IRAEs). A meta-analysis of the phase III Checkmate 017 (Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer), Checkmate 057 (Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer), and Keynote 010 (Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial) studies was performed to assess the type and frequency of these IRAEs.8 Adverse events of any grades based on the National Cancer Institute Common Terminology Criteria for Adverse Events occurred in 69% of patients, and adverse events grade 3 or higher occurred in 7% to 13% of patients.9, 10, 11 The most frequent IRAEs exhibit endocrinopathy (hypothyroidism 4%-8%, hyperthyroidism 0%-5%), skin rashes (5%-11%), and hepatitis (2%-11%). The most severe were pneumonitis (3%-5%), colitis (1%-2%), hypophysitis (2%), and adrenal failure (0%-1%).
The development of new targeted therapies sometimes leads to new adverse events.12, 13 In a totally different context, these adverse events have been assessed as markers of treatment outcomes. This is the case for skin rash and tyrosine kinase inhibitors efficacy,14 and we tried to find an analogy with ICIs and IRAEs.
A first trial published in November 2016 suggested a correlation between IRAEs and efficacy of ICIs in melanomas.15
To date, there is mainly 1 retrospective study with 134 patients16 and 2 prospective studies with 3817 and 43 patients,18 all treated with nivolumab only, suggesting an association between the occurrence of IRAEs and the efficacy of ICIs in NSCLC.
The primary endpoint of this study was to assess the association between IRAEs and overall survival (OS) of patients with advanced NSCLC. Our secondary endpoints were to assess the association between IRAEs (type and severity) and progression-free survival (PFS), as well as the objective response rate (ORR) and disease control rate (DCR).
Section snippets
Patients
In this observational retrospective study, data from all patients older than 18 years of age who were diagnosed with metastatic NSCLC at 2 centers and who received at least 1 cycle of ICI (anti-PD-L1 or anti-PD-1) alone or in combination from April 2, 2013 to February 14, 2017 were analyzed. Patients known to have any previously controlled autoimmune disease were excluded.
Before the data collection, all patients provided signed informed consent allowing the use of data collected during standard
Patient and Disease Characteristics
Overall, 270 patients treated with ICIs were retrieved from our database and analyzed. Patient and disease characteristics are summarized in Table 1. The median age was 61 years (IQR, 32-84 years), and there were more men (65.6%) than women (34.4%). Most patients (88.5%; n = 239) were current or former smokers. The most frequent mutations (34.8%; n = 94) were the KRAS mutations. Regarding the treatments with ICIs, 89.3% (n = 241) of the patients received an anti-PD1 antibody; with 91.4% (n =
Discussion
To the best of our knowledge, this study is the largest case series to assess the association between IRAEs and the efficacy of ICIs. Statistically significant differences were observed in the in OS, PFS, and ORR, in favor of the patients with IRAEs compared with the patients without any IRAEs. Subgroup analyses also showed better OS and PFS for patients with thyroid dysfunction.
The primary limitations of this trial are retrospective design and the low number of centers involved (2 centers).
Disclosure
The authors have stated that they have no conflicts of interest.
References (23)
- et al.
Immune checkpoint blockade
Hematol Oncol Clin North Am
(2014) - et al.
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Lancet
(2017) - et al.
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
Lancet Oncol
(2016) - et al.
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Lancet
(2016) - et al.
Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis of 24 trials
Lung Cancer
(2012) - et al.
Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab
Lung Cancer
(2018) - et al.
Early immune-related adverse events and association with outcome in advanced non–small cell lung cancer patients treated with nivolumab: a prospective cohort study
J Thorac Oncol
(2017) - et al.
Incidence of pneumonitis with use of Programmed Death 1 and Programmed Death-Ligand 1 inhibitors in non-small cell lung cancer: a systematic review and meta-analysis of trials
Chest
(2017) - et al.
Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer
Ann Oncol
(2017) - et al.
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
Lancet
(2016)
Cancer statistics, 2015
CA Cancer J Clin
Cited by (134)
ICI-based therapies: A new strategy for oral potentially malignant disorders
2023, Oral OncologyImmune checkpoint inhibitor-related pneumonitis: research advances in prediction and management
2024, Frontiers in Immunology